Inspections, Compliance, Enforcement, and Criminal Investigations

Size: px
Start display at page:

Download "Inspections, Compliance, Enforcement, and Criminal Investigations"

Transcription

1 Page 1 of 7 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations Zynex Medical, Inc. 6/27/14 Department of Health and Human Services Public Health Service Food and Drug Administration Denver District Office Building 20-Denver Federal Center P.O. Box Denver, Colorado TELEPHONE: June 27, 2014 WARNING LETTER VIA UPS Overnight Mr. Thomas Sandgaard Founder, Chairman and CEO Zynex Medical, Inc Park Meadows Drive Lone Tree, CO Dear Mr. Sandgaard: Ref: DEN WL During an inspection of your firm located in Lone Tree, Colorado on January 6, 2014 through January 21, 2014, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the NexWave multiple mode electrical stimulator and the IF8000 electrical stimulator. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act ( the Act ), 21 U.S.C. 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from David G. Empey, Director, Regulatory and Compliance, dated February 7, 2014, concerning our investigators observations noted on the Form FDA 483 (FDA 483), Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following: 1. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR (a). For example:

2 Page 2 of 7 a. Your firm s Complaint Handling procedure, revision 3, does not ensure complaints are evaluated to determine if they are reportable under part 21 CFR 803 (Medical Device Reporting). For example, The procedure states, The complaint coordinator will evaluate the complaint to determine if it involves any injury to the customer. If it does, an MDR report will be initiated. This complaint procedure will not ensure that complaints representing malfunctions, as defined in 21 CFR 803.3, which may cause or contribute to, a serious injury or death if they were to recur, will be identified. b. Your firm s Complaint Handling procedure, revision 3, states, The coordinator will determine if the complaint requires an investigation and further identifies that this determination will be documented in the complaint report. The procedure also states The investigation is documented on Complaint Evaluation Report. However, between December 13, 2012, and December 31, 2013, your firm documented (b)(4) customer complaints in your QA log and you did not document any product complaint reports for these complaints including any investigations. For example, there are no complaint reports for the following complaints: 1. Serial Number (SN) (b)(4) received 10/24/ SN (b)(4) received 10/22/ SN (b)(4) received 8/29/ SN (b)(4) received 5/17/ SN (b)(4) received 10/15/ SN (b)(4) received 10/24/ SN (b)(4) received 11/04/2013 We reviewed your firm s response and conclude that it is not adequate. Your response states, We will modify the procedure to base this [MDR Reportability] decision on whether a device related injury caused the customer to seek medical treatment This initial complaint evaluation would not allow your firm to identify malfunctions that may cause or contribute to a death or serious injury if they were to recur to ensure they are evaluated under your full MDR evaluations and investigations. Further, although your response states that you will update your complaint procedure, you did not provide a copy of the updated procedure; therefore, we are unable to evaluate your corrections at this time. 2. Failure to establish adequate procedures for design inputs as required by 21 CFR (c). For example: a. Your firm s Design Control procedure Revisions 01 and 02 do not include requirements to ensure the design requirements relating to the device are appropriate and address the intended use. Your firm did not define appropriate significant physical requirements, safety requirements, biocompatibility requirements, and reliability requirements for your NexWave multiple mode electrical stimulator. For example, your design inputs did not include requirements for the material of the unit, biocompatibility or sterility of the electrodes, battery and electrode shelf life, and user interface requirements. b. Your firm s Design Control procedure, revisions 01 and 02, do not include clear requirements identifying how your design inputs will be documented and approved. c. Your firm s Design Control procedure, revisions 01 and 02, do not include a mechanism for addressing incomplete, ambiguous, or conflicting requirements. We have reviewed your firm s response; however, the adequacy of the response cannot be determined at this time. Your response states that the design control procedures will be updated; however, you did not provide these procedures or sufficient information to allow for the evaluation

3 Page 3 of 7 of your response at this time. 3. Failure to establish procedures for design verification as required by 21 CFR (f). Specifically, your firm did not conduct a complete design verification of the software requirements of your NexWave multimode electrical stimulator. Your verification testing of the software did not include verifications to ensure all your software requirements were met. For example, verification testing did not include testing of the control/reset of the treatment timer, idle shut off functionality, and the treatment data storage functionality. We have reviewed your response and have concluded it is inadequate. Your response states you will update the design control SOP and verify detailed software specifications. However, you did not include evidence to show a comprehensive review of the verification activities of other aspects of your NexWave device. In addition, you did not provide sufficient details of the planned corrections to your design control procedures to allow for evaluation at this time. 4. Failure to establish a device master record (DMR) as required by 21 CFR Specifically, your firm s DMR consisted only of a bill of materials, which did not include or refer to the location of the device specifications, drawings, production process specifications, production methods, quality assurance procedures, and packaging specifications. We have reviewed your response; however, we cannot determine the adequacy of your response at this time. Your firm plans to generate a DMR that meets the requirements of 21 CFR ; however, without a review of the completed records, we cannot make a determination on the adequacy of your response. 5. Failure to maintain device history records (DHR) that contain all the information required by 21 CFR Specifically, our inspection identified (b)(4) DHRs that did not include the primary identification label and all acceptance records for the manufactured batches of NexWave multiple mode electrical stimulators. The DHRs for the following work orders were reviewed during the inspection and found to be deficient. (b)(4) (b)(4) We have reviewed your response and concluded it is inadequate. You have committed to drafting a procedure for maintaining DHRs. However, you did not address how your firm will retrospectively review your DHRs to identify all the deficient DHRs and correct them where possible. 6. Failure to establish procedures for corrective and preventive actions as required by 21 CFR (a). Specifically, your firm conducted an investigation and design changes to the (b)(4) of your NexWave device in May This investigation was conducted in response to complaints of the devices (b)(4). This investigation and subsequent design change constitute a corrective action. Although your firm has procedures describing how corrective actions should be investigated, documented, and evaluated for effectiveness, you did not document the described activities. We have reviewed your response and concluded it is inadequate. You have committed to revising your CAPA procedure. However, you did not address how your firm will retrospectively review any other corrective or preventive actions to ensure they are appropriately verified for effectiveness and documented.

4 Page 4 of 7 7. Failure to establish procedures for internal audits as required by 21 CFR Specifically, you did not complete your scheduled internal auditing activities as required by your 2013 auditing schedule. You did not conduct audits of your training, document control, management responsibility, CAPA, complaints, calibration, purchasing, or servicing systems during We have reviewed your response and have concluded that the adequacy of your response cannot be determined at this time. Your firm has committed to drafting new internal audit procedures; until you have completed internal audits and we can review these procedures, we cannot determine the adequacy of your response. MEDICAL DEVICE REPORTING Our inspection also revealed that the NexWave electrical stimulator is misbranded under Section 502(t)(2) of the Act, 21 U.S.C. 352(t)(2), in that your firm failed or refused to furnish material or information regarding the devices that is required by or under Section 519 of the Act, 21 U.S.C. 360i, and 21 CFR Part Medical Device Reporting. Significant deviations include, but are not limited to: 1. Failure to report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that you market malfunctioned and this device or a similar device that you market would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR (a)(2). For example, the events described in Complaints (b)(4), and an unnumbered complaint dated October 24, 2013, describe a malfunction occurring with the NexWave electrical stimulator. FDA considers a malfunction to be reportable if the following is true: (5) the manufacturer takes or would be required to take an action under sections 518 or 519(f) of the act as a result of the malfunction of the device or other similar devices. (Refer to the Medical Devices; Medical Device User Facility and Manufacturer Reporting, Certification and Registration Regulation, Federal Register Volume 60, Number 237, page 63585, comment 12. Please note that the preamble reference is section 519(f), but the appropriate designation for the section is now section 519(g) due to amendments to the FD&C Act). FDA determined that the 2009 field action conducted for the IF8000 electrical stimulator met the criteria for item 5 under the 1995 Preamble. The field action was conducted after you identified (b)(4) that could result in the device ceasing to operate, overheating and becoming hot to the touch. The fact that the malfunction occurred once leads to the presumption that the malfunction will recur. Accordingly, your firm should have reported the events occurring in NexWave Complaints (b)(4), and the unnumbered complaint dated October 24, 2013, to FDA as malfunctions on the form FDA 3500A. 2. Failure to adequately develop, maintain and implement written MDR procedures, as required by 21 CFR For example, after reviewing your firm s MDR procedure titled SOP Zynex Medical Device Reporting and Vigilance, Rev.2, the following issues were noted: a. There is no evidence that the procedure has been implemented. For example, there is no effective date for the procedure. b. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements. For example: There are no definitions of what your firm will consider to be a reportable event under 21 CFR

5 Page 5 of 7 Part 803. The exclusion of definitions from 21 CFR for the terms become aware, caused or contributed, malfunction, MDR reportable event, and serious injury, and definitions for the terms reasonably known and reasonably suggests, found respectively in 21 CFR (b) and (c)(1) may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR (a). c. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports. Specifically, the following are not addressed: Instructions for how to obtain and complete the FDA 3500A form. The procedure does not include the address for where to submit MDR reports: FDA, CDRH, Medical Device Reporting, P.O. Box 3002, Rockville, MD d. The procedure does not describe how your firm will address documentation and recordkeeping requirements, including: Systems that ensure access to information that facilitates timely follow-up and inspection by FDA. Your firm s procedure includes references to baseline reports. Baseline reports are no longer required and we recommend that all references to a Baseline Report be removed from your firm s MDR procedure (see: 73 Federal Register Notice 53686, dated September 17, 2008). Your firm s procedure also includes references to annual certifications. Annual certifications are no longer required and we recommend that all references to an Annual Certification be removed from your firm s MDR procedure (see: Fourth Notice, Federal Register, dated March 20, 1997: Medical Device Reporting; Annual Certification; Final rule). The adequacy of your firm s response, dated February 7, 2014 cannot be determined at this time. Your firm s response states that corrective actions are planned. However, your firm did not include documentation or evidence of the corrections. Without this documentation in hand, FDA cannot make an assessment with respect to adequacy. The emdr Final Rule requiring manufacturers and importers to submit electronic Medical Device Reports (emdrs) to FDA was published on February 13, The requirements of this final rule will take effect on August 14, If your firm is not currently submitting reports electronically, we encourage you to visit the following web link for additional information about the electronic reporting requirements: 1 If your firm wishes to discuss MDR reportability criteria or to schedule further communications, it may contact the Reportability Review Team by at CORRECTIONS AND REMOVALS Our inspection also revealed that your firm s IF8000 electrical stimulator devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. 360i, and 21 CFR Part 806 Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following: Failure to report a correction or removal, conducted to reduce a risk to health posed by a device, or

6 Page 6 of 7 remedy a violation caused by a device which may present a risk to health, in writing to FDA, as required by 21 CFR For example, on June 25, 2009, your firm initiated a removal of your IF8000 electrical stimulator after identifying that (b)(4) could result in the device ceasing to operate, overheating and becoming hot to the touch. Between June 25, 2009, and July 9, 2009, your firm sent approximately 2,978 recall letters to customers notifying them of the defect and requesting they contact your company. You did not notify FDA, in writing, within ten days of initiating this removal. We reviewed your firm s response and conclude that it is not adequate. Although you have submitted the subject removal to FDA, you did not address how you will verify that there were no other corrections or removals required to be reported to FDA that have not been reported. A follow up inspection will be required to assure that corrections and/or corrective actions are adequate. Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, premarket approval applications for Class III devices to which the Quality System regulation violations are reasonably related will not be approved until the violations have been corrected. Requests for Certificates to Foreign Governments will not be granted until the violations related to the subject devices have been corrected. Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and/or corrective actions (including any systemic corrections) that your firm has taken. If your firm s planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and/or corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm s response should be comprehensive and address all violations included in this Warning Letter. Your firm s response should be sent to: Denver District Office, 6 th & Kipling Street, PO BOX 25087, Denver, CO (Attn: Bryan Love, Acting Compliance Officer). If you have any questions about the contents of this letter, please contact: Mr. Love at (phone) or (fax). Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm s facility. It is your firm s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance. Sincerely, /S/ LaTonya M. Mitchell District Director Page Last Updated: 07/03/2014

7 Page 7 of 7 Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players. Accessibility Contact FDA Careers FDA Basics FOIA No Fear Act Site Map Transparency Website Policies U.S. Food and Drug Administration New Hampshire Avenue Silver Spring, MD Ph INFO-FDA ( ) FDA For Government For Press Combination Products Advisory Committees Science & Research Regulatory Information Safety Emergency Preparedness International Programs News & Events Training and Continuing Education Inspections/Compliance State & Local Officials Consumers Industry Health Professionals FDA Archive Links on this page: 1.

2014 > Ambco Electronics, A California Corp 9/26/14

2014 > Ambco Electronics, A California Corp 9/26/14 Page 1 of 6 U.S. Food and Drug Administration Protecting and Promoting Your Health Ambco Electronics, A California Corp 9/26/14 Department of Health and Human Services Public Health Service Food and Drug

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations

More information

Soft Computer Consultants, Inc. 4/30/15

Soft Computer Consultants, Inc. 4/30/15 Soft Computer Consultants, Inc. 4/30/15 Department of Health and Human Services Public Health Service Food and Drug Administration Florida District 555 Winderley Place, Suite 200 Maitland, Florida 32751

More information

WARNING LETTER JUL 29, 2015

WARNING LETTER JUL 29, 2015 U.S. Food and Drug Administration Protecting and Promoting Your Health Cane S.p.A. 7/29/15 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Jabones Pardo S.A.

More information

Warning Letters > Inovo, Inc 2/19/15. Department of Health and Human Services Public Health Service Food and Drug Administration

Warning Letters > Inovo, Inc 2/19/15. Department of Health and Human Services Public Health Service Food and Drug Administration Page 1 of 5 U.S. Food and Drug Administration Protecting and Promoting Your Health Inovo, Inc 2/19/15 Department of Health and Human Services Public Health Service Food and Drug Administration Florida

More information

Overview of FDA Compliance for Medical Devices

Overview of FDA Compliance for Medical Devices Glisland Training Series: Overview of FDA Compliance for Medical Devices Glisland, Inc. San Jose, California, USA http://www.glisland.com Description This course provides a concise overview of how FDA

More information

Medical Device Reporting (MDR) 21 CFR Part 803

Medical Device Reporting (MDR) 21 CFR Part 803 Medical Device Reporting (MDR) 21 CFR Part 803 1 Objectives Review applicable sections of 21 CFR 803 and 21 CFR 820 Review and explain MDR reporting requirements Review FDA-483 observation examples 2 Medical

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations

More information

FDA Inspections: an investigator s perspective

FDA Inspections: an investigator s perspective FDA Inspections: an investigator s perspective Lori S. Lawless Medical Device Specialist Supervisory Consumer Safety Officer Food & Drug Administration Baltimore District Lori.Lawless@fda.hhs.gov (410)

More information

The Quality System Inspection Technique: What is QSIT? Quality System s Subsystems QSIT

The Quality System Inspection Technique: What is QSIT? Quality System s Subsystems QSIT The Quality System Inspection Technique: QSIT 1 What is QSIT? Moves FDA closer to Global Harmonization guideline for regulatory auditing of quality systems of medical device manufacturers Incorporates

More information

Specialty Medicine Compounding Pharmacy, P.C. 8/31/15

Specialty Medicine Compounding Pharmacy, P.C. 8/31/15 Specialty Medicine Compounding Pharmacy, P.C. 8/31/15 Department of Health and Human Services Public Health Service Food and Drug Administration Detroit District 300 River Place Suite 5900 Detroit, Ml

More information

Case 1:15-cv Document 1 Filed 02/03/15 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE

Case 1:15-cv Document 1 Filed 02/03/15 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE Case 1:15-cv-00041 Document 1 Filed 02/03/15 Page 1 of 12 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW HAMPSHIRE UNITED STATES OF AMERICA, Plaintiff, v. Civil Action No. ATRIUM MEDICAL CORP.,

More information

IVD Regulation Overview. Requirements to Assure Quality & Effectiveness

IVD Regulation Overview. Requirements to Assure Quality & Effectiveness IVD Regulation Overview Requirements to Assure Quality & Effectiveness CLIAC Jan. 2002 Statutory and Regulatory Requirements Statute: Food, Drug, and Cosmetic Act Food and Drugs Act of 1906 Food and Drug

More information

ORACLE CONSULTING GROUP

ORACLE CONSULTING GROUP ORACLE CONSULTING GROUP 9 Golder Ranch Rd., Ste. 1 Tucson, Arizona 9 Web Site: E-mail: 20-2-0 20-2-0 (FAX) CONSULTING MEMORANDUM QUALITY SYSTEM INSPECTION TECHNIQUE

More information

Guidance for Industry. Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products

Guidance for Industry. Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products Guidance for Industry Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products Small Entity Compliance Guide Written comments and suggestions may be

More information

MDR: Failures, Successes and Solutions

MDR: Failures, Successes and Solutions FDA Medical Device Industry Coalition MDR: Failures, Successes and Solutions Scott Eden, Sr. Director Quality and Regulatory Agenda Brief Overview of the Requirements Highlight MDR Failures Discuss some

More information

The emdr Challenge Test Your Adverse Event Reporting and Implementation Expertise

The emdr Challenge Test Your Adverse Event Reporting and Implementation Expertise The emdr Challenge Test Your Adverse Event Reporting and Implementation Expertise Steve Niedelman, Lead Quality Systems and Compliance Consultant, King and Spalding; former FDA Deputy Associate Commissioner

More information

Recall Communication: Medical Device Model Press Release Ron Brown

Recall Communication: Medical Device Model Press Release Ron Brown Recall Communication: Medical Device Model Press Release Ron Brown SLIDE 1 Welcome to CDRH Learn. CDRH Learn is a training program developed by FDA's Center for Devices and Radiological Health. It's designed

More information

ISO Compliance Checklist

ISO Compliance Checklist ISO 13485 Compliance Checklist FDA-ISO QMS Audit Checklist developed by greenlight.guru Audit #: Dates: Lead Auditor: NC = Non-Conformance OFI = Opportunity for Improvement PP = Positive Practice A = Acceptable

More information

Sandoz Private Limited 10/22/15

Sandoz Private Limited 10/22/15 Sandoz Private Limited 10/22/15 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 Warning Letter VIA UPS WL: 320-16-01 October 22, 2015

More information

UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES

UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES UNITED STATES OF AMERICA BEFORE THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES In the Matter of Dendy Foods, Inc. d/b/a Grocer s Pride ADMINISTRATIVE COMPLAINT FOR CIVIL MONEY

More information

Managing Effective US Medical Device Recalls. Rita R. Hoffman, RAC (Former FDA/CDRH Recall Chief) RHoffman, Inc

Managing Effective US Medical Device Recalls. Rita R. Hoffman, RAC (Former FDA/CDRH Recall Chief) RHoffman, Inc Managing Effective US Medical Device Recalls Rita R. Hoffman, RAC (Former FDA/CDRH Recall Chief) RHoffman, Inc ritarhoffman@gmail.com Discussion Points Definitions Responsibilities of Regulated Firms To

More information

Corrective and Preventive Action Background & Examples Presented by:

Corrective and Preventive Action Background & Examples Presented by: Corrective and Preventive Action Background & Examples Presented by: Kimberly Lewandowski-Walker Food and Drug Administration Division of Domestic Field Investigations Office of Regulatory Affairs Overview

More information

UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES

UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES In the Case of: Center for Tobacco Products, Complainant, v. NNMK Inc. d/b/a

More information

August 21, 2015. TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom

August 21, 2015. TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 Mr. Iain Alligan Technical

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations HomeInspections, Compliance, Enforcement, and Criminal InvestigationsEnforcement ActionsWarning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Cytosport Inc 6/29/11 Department

More information

GxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations

GxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations GxP Process Management Software : Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations Most FDA violations involve one of the following: Not having procedures in a regulated area

More information

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY JOYCE R. BRANDA Acting Assistant Attorney General JONATHAN F. OLIN Deputy Assistant Attorney General Civil Division U.S. Department of Justice PAUL J. FISHMAN United States Attorney District of New Jersey

More information

Triangle Compounding 11/2/15

Triangle Compounding 11/2/15 Triangle Compounding 11/2/15 Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District 60 Eighth Street NE Atlanta, GA 30309 November 2, 2015 VIA UNITED

More information

Moehs Cantabra, S.L. 4/14/11

Moehs Cantabra, S.L. 4/14/11 Moehs Cantabra, S.L. 4/14/11 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring MD 20993 Warning Letter VIA UPS MAIL WL: 320-11-011 April 14, 2011

More information

itac solutions for the medical industry Quality assurance of the highest standard FDA-compliant. Reliable. Productive.

itac solutions for the medical industry Quality assurance of the highest standard FDA-compliant. Reliable. Productive. Quality assurance of the highest standard FDA-compliant. Reliable. Productive. Market Requirements 1 Statutory regulations and stringent requirements laid down by the American regulatory authority, FDA

More information

Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8

Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8 Case 1:15-cv-23419-XXXX Document 1 Entered on FLSD Docket 09/10/2015 Page 1 of 8 IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF FLORIDA UNITED STATES OF AMERICA, ) ) Plaintiff, ) ) v.

More information

Subpart A--General Provisions

Subpart A--General Provisions [Code of Federal Regulations] [Title 21, Volume 8] [Revised as of September 27, 2016] [CITE: 21CFR820] Subpart A--General Provisions 820.1 Scope. a) Applicability. TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD

More information

Santa Fe Natural Tobacco Company, Inc. 8/27/15

Santa Fe Natural Tobacco Company, Inc. 8/27/15 U.S. Food and Drug Administration Protecting and Promoting Your Health Santa Fe Natural Tobacco Company, Inc. 8/27/15 SHARE (HTTPS://WWW.FACEBOOK.COM/SHARER/SHARER.PHP? U=HTTP%3A%2F%2FWWW.FDA.GOV%2FICECI%2FENFORCEMENTACTIONS%2FWARNINGLETTERS%2F2015%2FUCM4597

More information

October 28, 2015. Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS

October 28, 2015. Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 October 28, 2015 Cavex

More information

Responding to FDA 483s and Warning Letters

Responding to FDA 483s and Warning Letters Presentation to Parenteral Drug Association Responding to FDA 483s and Warning Letters Date: 2006 May 17 Introduction Main points of discussion: Brief Historical Overview Form FDA 483 Responding to the

More information

UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES

UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES UNITED STATES OF AMERICA BEFORE THE DEPARTMENTAL APPEALS BOARD CIVIL REMEDIES DIVISION DEPARTMENT OF HEALTH AND HUMAN SERVICES In the Case of: Center for Tobacco Products, Complainant, v. J Triple B LLC

More information

CHAPTER 7 - RECALL ACTIVITIES

CHAPTER 7 - RECALL ACTIVITIES CHAPTER 7 INVESTIGATIONS OPERATIONS MANUAL 2015 CONTENTS CHAPTER 7 - RECALL ACTIVITIES 7.1.1.1 - Recall SUBCHAPTER 7.1 - RECALLS... 368 7.1.1 - DEFINITIONS... 368 7.1.1.1 - Recall... 368 7.1.1.2 - Recall

More information

Client Alert. Supreme Court Rules State Law Tort Claims Involving Drug Labels Approved by FDA Are Not Preempted

Client Alert. Supreme Court Rules State Law Tort Claims Involving Drug Labels Approved by FDA Are Not Preempted Contact Attorney Regarding This Matter: Jennifer S. Blakely 404.873.8734 - direct 404.873.8735 - fax jennifer.blakely@agg.com William H. Kitchens 404.873.8644 - direct 404.873.8645 - fax william.kitchens@agg.com

More information

Planning for and Managing FDA Inspections. Focus: 21 CFR, Part 820

Planning for and Managing FDA Inspections. Focus: 21 CFR, Part 820 Planning for and Managing FDA Inspections Focus: 21 CFR, Part 820 Information, Preventive Action and Strategy 1 The Authority behind Inspections The Safe Medical Devices Act of 1990 (the SMDA), enacted

More information

Documents, Records and Change Control

Documents, Records and Change Control Documents, Records and Change Control Lori S. Lawless Medical Device Specialist Food and Drug Administration Baltimore District Office Lori.Lawless@fda.hhs.gov (410) 779-5442 May 13-14, 2008 Baltimore

More information

Corrective and Preventive Actions

Corrective and Preventive Actions Corrective and Preventive Actions A Five Step Approach Topics to Be Covered What is CAPA? Governing authority Five steps to a good CAPA process Where companies have difficulty Example citations Recap What

More information

Guidance for Industry

Guidance for Industry Guidance for Industry FDA Export Certificates Submit comments and suggestions regarding this document at anytime to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane,

More information

January 12, 2016. Dear Amy Yang:

January 12, 2016. Dear Amy Yang: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 January 12, 2016 Amy

More information

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors

Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors Information Sheet Guidance For IRBs, Clinical Investigators, and Sponsors FDA Institutional Review Board Inspections Additional copies are available from: Office of Good Clinical Practice Office of Special

More information

Corden Pharma Latina S.p.A. 5/20/16

Corden Pharma Latina S.p.A. 5/20/16 Corden Pharma Latina S.p.A. 5/20/16 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 Via UPS Warning Letter 320-16-14 Return Receipt Requested

More information

How to Respond to an FDA Warning Letter or 483 Observation

How to Respond to an FDA Warning Letter or 483 Observation How to Respond to an FDA Warning Letter or 483 Observation The odds of receiving an Inspectional Observation (483) or a subsequent Warning Letter are sharply on the rise, and the seriousness of each remains

More information

ORACLE CONSULTING GROUP

ORACLE CONSULTING GROUP ORACLE CONSULTING GROUP An Official United States Agent Firm for Foreign Establishments CONSULTING MEMORANDUM: DEALING WITH A MEDICAL DEVICE IN THE U.S. 5398 Golder Ranch Rd., Ste. 1 Tucson, Arizona 85739

More information

2 of 10 2/19/2014 9:08 AM

2 of 10 2/19/2014 9:08 AM 1 of 10 2/19/2014 9:08 AM Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Baxter

More information

Agency Information Collection Activities; Submission for Office of Management and Budget

Agency Information Collection Activities; Submission for Office of Management and Budget This document is scheduled to be published in the Federal Register on 08/03/2015 and available online at http://federalregister.gov/a/2015-18911, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

Current Good Manufacturing Practices, and FDA Enforcement Actions and Inspections

Current Good Manufacturing Practices, and FDA Enforcement Actions and Inspections Current Good Manufacturing Practices, and FDA Enforcement Actions and Inspections John R. Fleder, Esq. Holly S. Tucker Hyman, Phelps & McNamara, P.C. jrf@hpm.com hst@hpm.com www.hpm.com FDA GMP Repackaging

More information

FDA s Involvement with Standards. Inspecting the Packaging Process

FDA s Involvement with Standards. Inspecting the Packaging Process FDA s Involvement with Standards Inspecting the Packaging Process FDA s Involvement with Standards Food, Drug and Modernization Act 1997 section 514 Requires CDRH to be involved standards recognition.

More information

Medical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration

Medical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Medical Device Reporting Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Session Overview Purpose: To provide information about the

More information

FDA Regulation of Medical Devices

FDA Regulation of Medical Devices FDA Regulation of Medical Devices Bradley Merrill Thompson Interpharm Press, Inc. Buffalo Grove, IL Dedication Acknowledgments Introduction xv xvi xvii Part I. Overview Chapter 1. The History of Medical

More information

Risk Management: A Regulatory Perspective

Risk Management: A Regulatory Perspective Risk Management: A Regulatory Perspective Timothy A. Ulatowski Director, Office of Compliance, Center for Devices and Radiological Health USA Food and Drug Administration Beijing October 2008 Agenda Part

More information

March 20, 2015. Dear Mr. Chen:

March 20, 2015. Dear Mr. Chen: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 March 20, 2015 Biomate

More information

S.R. Burzynski Manufacturing Facility 6/13/16

S.R. Burzynski Manufacturing Facility 6/13/16 U.S. Food and Drug Administration Protecting and Promoting Your Health S.R. Burzynski Manufacturing Facility 6/13/16 Department of Health and Human Services Public Health Service Food and Drug Administration

More information

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance U.S. Department of Health and Human Services Food and Drug Administration Center for

More information

R430. Health, Health Systems Improvement, Child Care Licensing.

R430. Health, Health Systems Improvement, Child Care Licensing. R430. Health, Health Systems Improvement, Child Care Licensing. R430-3. General Child Care Facility Rules Inspection and Enforcement. R430-3-1. Legal Authority and Purpose. This rule is adopted pursuant

More information

Submission information

Submission information 510(k) Summary Submitter information Company name Materialise N.V. Establishment registration number 3003998208 Street Address Technologielaan 15 City Leuven Postal code 3001 Country Belgium Phone number

More information

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC Guidance for Industry Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act: Questions

More information

Guide for Custom-Made Dental Device Manufacturers on Compliance with European Communities (Medical Devices) Regulations, 1994

Guide for Custom-Made Dental Device Manufacturers on Compliance with European Communities (Medical Devices) Regulations, 1994 Guide for Custom-Made Dental Device Manufacturers on Compliance with European Communities (Medical SUR-G0014-1 12 NOVEMBER 2013 This guide does not purport to be an interpretation of law and/or regulations

More information

2016 > Emcure Pharmaceuticals Limited 3/3/16

2016 > Emcure Pharmaceuticals Limited 3/3/16 Seite 1 von 7 U.S. Food and Drug Administration Protecting and Promoting Your Health Emcure Pharmaceuticals Limited 3/3/16 Department of Health and Human Services Public Health Service Food and Drug Administration

More information

May 5, 2015. Dear Mr. Courtney:

May 5, 2015. Dear Mr. Courtney: DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 May 5, 2015 Terumo Cardiovascular

More information

Device Manufacture Inspections by the FDA

Device Manufacture Inspections by the FDA Device Manufacture Inspections by the FDA Lance D. Johnson LDJCG LLC in Cooperation with axxos Copyright 2008 Lance D Johnson Consulting Group. All Rights Reserved. FDA History 1976 Medical Device Amendments

More information

Simpler Implant Solutions Inc. 2930 Arbutus St. Vancouver, BC V6i 3Y9. haroldbergmanl~ogmail.com 604 736 9890 Telephone 604 736 9747 Fax K080115

Simpler Implant Solutions Inc. 2930 Arbutus St. Vancouver, BC V6i 3Y9. haroldbergmanl~ogmail.com 604 736 9890 Telephone 604 736 9747 Fax K080115 APR 5 2013 Summary: K121281 Submitter: Company Address Contact Person: Simpler Implant Solutions Inc. 2930 Arbutus St. Vancouver, BC V6i 3Y9 Dr. Harold Bergman haroldbergmanl~ogmail.com 604 736 9890 Telephone

More information

GE Healthcare MAR 1 2013

GE Healthcare MAR 1 2013 K130155 Pagel1 of 2 GE Healthcare MAR 1 2013 510(k) Summary In accordance with 21 CFR 807.92 the following summary of information is provided: Submitter: Primary Contact Person: Secondary Contact Person:

More information

February 5, 2015. Dear Kristin Pabst,

February 5, 2015. Dear Kristin Pabst, DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 February 5, 2015, Inc.

More information

Section 5: Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP)

Section 5: Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP) Section 5: Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP) 1 Quality Systems Regulation (QSR) 2 Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP) Sets of checks

More information

How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters

How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters environmental failure analysis & prevention health technology development How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters Kevin L. Ong, Ph.D., P.E. Managing

More information

Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation

Medical Devices; Cardiovascular Devices; Classification of the Esophageal Thermal Regulation This document is scheduled to be published in the Federal Register on 08/18/2015 and available online at http://federalregister.gov/a/2015-20317, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

General Provisions Subpart A Scope The Quality System

General Provisions Subpart A Scope The Quality System General Provisions Subpart A Scope The Quality System 20 Scope 820.1 SCOPE (a) Applicability. (1) Current good manufacturing practice (CGMP) requirements are set forth in this quality system regulation.

More information

October 28, ncontact Surgical, Inc. VP of Regulatory and Quality 1001 Aviation Parkway, Suite 400 Morrisville, North Carolina 27560

October 28, ncontact Surgical, Inc. VP of Regulatory and Quality 1001 Aviation Parkway, Suite 400 Morrisville, North Carolina 27560 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002 October 28, 2014 ncontact

More information

Medical devices recall guide

Medical devices recall guide Medical devices recall guide GUI-0054 November 3, 2016 Medical devices recall guide (GUI-0054) Author: Health Canada Date issued: November 3, 2016 Date implemented: November 3, 2016 Replaces: Guidance

More information

Contains Nonbinding Recommendations

Contains Nonbinding Recommendations FY 2016 Medical Device User Fee Small Business Qualification and Certification Guidance for Industry, Food and Drug Administration Staff and Foreign Governments Document issued on August 3, 2015. As of

More information

September 17, 2014. Keeler Instruments Inc. Mr. Eugene R. Van Arsdale Marketing Manager 459 Parkway Broomall, PA 19008

September 17, 2014. Keeler Instruments Inc. Mr. Eugene R. Van Arsdale Marketing Manager 459 Parkway Broomall, PA 19008 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 September 17, 2014 Keeler

More information

Datrix, Inc NOV - 1 2005. Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System

Datrix, Inc NOV - 1 2005. Appendix G. 510(k) Summary of Safety and Effectiveness for Datrix, Inc CardioServer ECG Management System Appendix G NOV - 1 2005 510(k) Summary of Safety and Effectiveness for CardioServer ECG Management System 1. DATE SUMMARY PREPARED: 9-26-2005 2. SUBMITTER'S NAME AND ADDRESS: Linda Gluckman 340 State Place

More information

HOW TO DEAL IN A REGULATED ENVIRONMENT. Matt Rigerman Director Operations & Quality Reichert, Inc. CMQ/OE, CSSBB, CQA

HOW TO DEAL IN A REGULATED ENVIRONMENT. Matt Rigerman Director Operations & Quality Reichert, Inc. CMQ/OE, CSSBB, CQA HOW TO DEAL IN A REGULATED ENVIRONMENT Matt Rigerman Director Operations & Quality Reichert, Inc. CMQ/OE, CSSBB, CQA AGENDA Origin of the FDA Medical Devices standard (21 CFR 820) Compliance strengthens

More information

Inspection of Medical Device Manufacturers

Inspection of Medical Device Manufacturers Inspection of Medical Device Manufacturers Document issued on: June 15, 2006 PROGRAM 7382.845 SUBJECT: INSPECTION OF MEDICAL DEVICE MANUFACTURERS IMPLEMENTATION DATE: June 15, 2006 (Previous editions obsolete.)

More information

Medical Device Reporting (MDR) Requirements the New FDA Draft Guidance

Medical Device Reporting (MDR) Requirements the New FDA Draft Guidance Medical Device Reporting (MDR) Requirements the New FDA Draft Guidance February 27, 2014 Jeffrey K. Shapiro (202) 737-9633 jshapiro@hpm.com 1 Essential Requirements n Submit MDR reportable events to FDA

More information

February 22, 2015. Life Spine, Incorporated Mr. Randy Lewis General Manager 2401 West Hassell Road, Suite 1535 Hoffman Estates, Illinois 60169

February 22, 2015. Life Spine, Incorporated Mr. Randy Lewis General Manager 2401 West Hassell Road, Suite 1535 Hoffman Estates, Illinois 60169 DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 10903 New Hampshire Avenue Document Control Center WO66-G609 Silver Spring, MD 20993-0002 February 22, 2015 Life Spine, Incorporated Mr. Randy

More information

Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act

Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act Reprinted from FDA s website by EAS Consulting Group, LLC Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE

More information

Northwest Cardiology Associates 400 W. Northwest Hwy Barrington, IL 60010 847.382.4600 Fax 847.382.1771. HIPAA Notice of Privacy Practices ( Notice )

Northwest Cardiology Associates 400 W. Northwest Hwy Barrington, IL 60010 847.382.4600 Fax 847.382.1771. HIPAA Notice of Privacy Practices ( Notice ) Northwest Cardiology Associates 400 W. Northwest Hwy Barrington, IL 60010 847.382.4600 Fax 847.382.1771 HIPAA Notice of Privacy Practices ( Notice ) THIS NOTICE DESCRIBES HOW INFORMATION ABOUT YOU MAY

More information

AW Server 510 (k) Summary of Safety and Effectiveness

AW Server 510 (k) Summary of Safety and Effectiveness SEP 2 2008 GE Medical Systems AW Server 510 (k) Summary of Safety and Effectiveness This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of 21 CFR

More information

Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection

Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection U.S. Department of Health and Human Services Food and Drug Administration Office of Regulatory

More information

510(k) summary APR

510(k) summary APR 510(k) summary APR 19 2013 (in accordance to 21 C.F.R. 807.92) Submitter Identification Holder / Headquarters: MIE GmbH Hauptstrasse 112 23845 Seth, Schleswig-Holstein Germany Telephone Number: +49 4194

More information

Document issued on: March 19, The draft of this document was issued on May 20, 2010.

Document issued on: March 19, The draft of this document was issued on May 20, 2010. Guidance for Industry, Third Parties and Food and Drug Administration Staff Medical Device ISO 13485:2003 Voluntary Audit Report Submission Pilot Program Document issued on: March 19, 2012 The draft of

More information

Guidance for Industry. Required Warnings for Cigarette Packages and Advertisements

Guidance for Industry. Required Warnings for Cigarette Packages and Advertisements Guidance for Industry Required Warnings for Cigarette Packages and Advertisements Small Entity Compliance Guide Written comments and suggestions may be submitted at any time for Agency consideration to

More information

LIFESTREAM BEHAVIORAL CENTER, INC. JOINT NOTICE OF PRIVACY PRACTICES. Effective Date: April 14, 2003

LIFESTREAM BEHAVIORAL CENTER, INC. JOINT NOTICE OF PRIVACY PRACTICES. Effective Date: April 14, 2003 LIFESTREAM BEHAVIORAL CENTER, INC. JOINT NOTICE OF PRIVACY PRACTICES Effective Date: April 14, 2003 THIS DOCUMENT DESCRIBES HOW MEDICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED AND HOW YOU CAN GET

More information

PART 820 QUALITY SYSTEM REGULATION

PART 820 QUALITY SYSTEM REGULATION Pt. 820 (v) A summary of any changes made to the device in accordance with supplements submitted under 814.108. If information provided in the periodic reports, or any other information in the possession

More information

Empowering the Quality and Regulatory Compliance Functions

Empowering the Quality and Regulatory Compliance Functions Empowering the Quality and Regulatory Compliance Functions Management must take steps to ensure that regulatory and quality compliance is everyone s responsibility. By: J. Glenn George, Kenneth Imler,

More information

Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry

Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for

More information

Prevent Quality System Deficiencies by Conducting Effective Internal Audits WHITE PAPER

Prevent Quality System Deficiencies by Conducting Effective Internal Audits WHITE PAPER Prevent Quality System Deficiencies by Conducting Effective Internal Audits WHITE PAPER An internal audit system is one of the most effective ways to monitor, analyze, control, and improve quality management

More information

Q(K SVJM~jPagelIof 3

Q(K SVJM~jPagelIof 3 K13 0460 Q(K SVJM~jPagelIof 3 JUL 1 12013 This 51 0(k) Summary is being submitted in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content contained in this 510(k)

More information

Preparing for an FDA Pre-Approval Inspection (PAI)

Preparing for an FDA Pre-Approval Inspection (PAI) Preparing for an FDA Pre-Approval Inspection (PAI) Jorge Torres CMQ/OE, CQE, CQA July, 2007 1 Agenda Introduction Understanding the PAI Experience: What to Expect Inspection Management Plan Preparing for

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: July 2015

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: July 2015 Third-Party Auditor/Certification Body Accreditation for Food Safety Audits: Model Accreditation Standards Draft Guidance for Industry and Food and Drug Administration Staff DRAFT GUIDANCE This guidance

More information

The Shifting Sands of Medical Software Regulation

The Shifting Sands of Medical Software Regulation The Shifting Sands of Medical Software Regulation Suzanne O Shea Ralph Hall September 10, 2014 What Software is Regulated by FDA? FDA regulates medical devices. FDA regulates software that meets the definition

More information

F D A R E G U L A T O R Y S e p t e m b e r

F D A R E G U L A T O R Y S e p t e m b e r F D A R E G U L A T O R Y 1 0 1 S e p t e m b e r 2 0 1 6 2 A G E N D A Definition of a medical device Device classification Developing a Regulatory Strategy Example of new device to be marketed 510(k)

More information